<DOC>
	<DOCNO>NCT00002589</DOCNO>
	<brief_summary>RATIONALE : Treating person 's lymphocyte interleukin-2 monoclonal antibody may help kill cancer cell put back body . PURPOSE : This phase II trial study well lymphocyte therapy work treat patient stage III stage IV kidney cancer .</brief_summary>
	<brief_title>Lymphocyte Therapy Treating Patients With Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate ability autologous lymphocyte therapy ( ALT ) give adjuvant therapy follow nephrectomy and/or complete surgical resection metastatic disease delay prevent metastatic recurrence patient high-risk renal cell carcinoma . - Determine incidence tumor recurrence survival patient treat regimen . - Determine toxicity/morbidity regimen patient . - Explore relationship clinical response vitro autologous lymphocyte characteristic , include lytic activity , cytokine production , response cytokine , phenotypic profile patient treat regimen . - Assess patient immune status , , therapy . OUTLINE : Patients stratify accord postnephrectomy interval ( le 3 month vs 3 month ) , extent lymph node involvement ( N1 vs N2-N3 ) , interleukin-1 concentration initial autologous lymphocyte culture ( le 500 pg/mL v great 500 pg/mL ) , prenephrectomy treatment . Mononuclear cell collected apheresis day 1 culture interleukin-2 monoclonal antibody OKT3 . After cellular production , autologous lymphocyte reinfused least 30 minute . Treatment repeat monthly 6 month every 3 month 6 month absence unacceptable toxicity . Patients follow every 3 month 1 year , every 6 month 1 year , annually 5 year . PROJECTED ACCRUAL : A total 10-90 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Muromonab-CD3</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document completely resect stage III stage IV renal cell carcinoma , clinically stag within 2 month prior initiation therapy No evidence nephrotic syndrome PATIENT CHARACTERISTICS : Age : Over 16 Performance status : ECOG 02 Hematopoietic : WBC least 3,000/mm^3 Granulocyte count least 1,500/mm^3 Platelet count 50,000/mm3 500,000/mm^3 Hemoglobin least 10 g/dL No hematologic abnormality Hepatic : PT great 1.5 time control PTT le 1.5 time control Hepatitis B surface antigen negative Renal : Creatinine great 4.0 mg/dL Calcium great 12 mg/dL No symptomatic hypercalcemia Cardiovascular : No uncontrolled severe cardiac disease , e.g . : No myocardial infarction within 6 month No congestive heart failure Other : HIV negative No significant organ dysfunction No serious medical illness would limit life expectancy No significant CNS disease include uncontrolled untreated psychiatric seizure disorder No uncontrolled bacterial , viral , fungal infection No active peptic duodenal ulcer Adequate peripheral venous access require No prior malignancy within past 5 year except inactive nonmelanoma skin cancer carcinoma situ cervix Not pregnant Negative pregnancy test PRIOR CONCURRENT THERAPY : No concurrent postnephrectomy adjuvant therapy Biologic therapy : No concurrent immunotherapy Chemotherapy : No concurrent chemotherapy Endocrine therapy : More 1 week since prior corticosteroid ( except inhalation therapy respiratory ailment replacement adrenal insufficiency ) No concurrent therapy following : Estrogens ( except postmenopausal replacement therapy ) Androgens Progestins Antiestrogens Antiandrogens LHRH analogue antagonists Other hormone Radiotherapy : Not specify Surgery : See Disease Characteristics No prior solid organ allograft More 3 week since major surgery , include nephrectomy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>